The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state studyCOVID-19 환자의 호흡 지원 상태 전환 및 임상 결과에 대한 토실리주맙의 영향. 마르코프 모델 다중 상태 연구Observational Study Published on 2021-08-122022-09-12 Journal: PLoS ONE [Category] 임상, 진단, [키워드] 95% CI Analysis approach benefit Clinical outcome clinical trials contributing to COVID pneumonia COVID-19 patients death Decision making disease disease stage Endpoint heterogeneous hospital IMV invasive Invasive mechanical ventilation management Markov Mortality NIV no respiratory support Non-invasive non-invasive ventilation observational study oxygen Oxygen therapy Patient positive Prevalence Probability randomized clinical trial reduced risk Respiratory Support Result sequence Support switching Time to recovery Tocilizumab tocilizumab administration treated was used [DOI] 10.1371/journal.pone.0251378 PMC 바로가기 [Article Type] Observational Study
Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trialResearch Paper Published on 2021-06-272022-10-04 Journal: EClinicalMedicine [Category] 신약개발, 임상, [키워드] 1:1 95% CI 95% confidence interval accelerate Adverse adverse events assigned baseline clearance Cohort collected conducted COVID-19 COVID-related symptoms cycle threshold develop died drug discontinuation early treatment Effect emtricitabine Endpoint enrolled enrolment event finding France fumarate funding gastrointestinal side effect hospital hospitalisation in both groups Inclusion increase in Infection interfere IQR less median nasopharyngeal Nasopharyngeal swab Open-label Other Outpatient Patient per day phase 2 trial pilot study Randomized Randomly RdRP receive Registered reported RNA polymerase RT-PCR SARS CoV-2 SARS-COV-2 infection SARS-CoV-2 viral SARS-CoV-2 viral load secondary endpoint severe COVID-19 Standard of care Support symptom onset tenofovir therapy Time to recovery treated treatment group Trial viral burden [DOI] 10.1016/j.eclinm.2021.100993 PMC 바로가기 [Article Type] Research Paper
Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial경증 내지 중등도의 COVID-19 환자의 증상 회복에 대한 2 주 5000 IU 대 1000 IU 비타민 D3 보충의 효과 : 무작위 임상 시험Randomized Controlled Trial Published on 2021-06-242022-08-13 Journal: Nutrients [Category] MERS, SARS, 임상, [키워드] adjusted adjuvant therapy Admission age Ageusia Anthropometrics baseline blood glucose blood sample Blood samples BMI both groups caused Chain Reaction clinical clinical parameter clinical trial clinically comparison Comparisons cough COVID-19 COVID-19 disease COVID-19 severity COVID-19 symptom COVID-19 symptoms D-dimer determine disease Effect fasting females full recovery Glucose gustatory sensory loss Hospitalized IL-6 IL-6 level IL-6 levels in both group increased risk Inflammatory marker inflammatory markers Kaplan–Meier survival analysis lipids loss of taste Mild mild to moderate mild to moderate COVID-19 disease Moderate COVID-19 on admission once daily oral vitamin D3 overtime P -value p -values Patient polymerase chain polymerase chain reaction positive randomized clinical trial receive reduce reverse transcriptase Reverse transcriptase polymerase chain reaction RT-PCR SARS-CoV-2 saudi serum Sex short duration significant decrease significant increase significantly shorter Study design survival analysis Symptom Symptoms Taste therapy for COVID-19 Time to recovery transcriptase Vitamin D vitamin D deficiency vitamin D insufficiency Vitamin D status Vitamin D supplementation Vitamin D3 were measured [DOI] 10.3390/nu13072170 PMC 바로가기 [Article Type] Randomized Controlled Trial
Time to recovery from COVID-19 and its predictors among patients admitted to treatment center of Wollega University Referral Hospital (WURH), Western Ethiopia: Survival analysis of retrospective cohort studyResearch Article Published on 2021-06-102022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] 95% CI Admission age AhR Analysis association being Comorbidities Comorbidity conducted COVID-19 COVID-19 case Cox regression analysis Cox regression model data entry determine effective Ethiopian Factor Fever hazard identify illnesses incidence rate independent predictor IQR median time mild infection multivariable observation Older age P-value Patient patients with COVID-19 predictor Ratio recommendation reduce Referral Regression model Result retrospective cohort study selected Seven Spread Stata statistically significant survival analysis Symptom the median time Time to recovery Treatment university Vaccine was used WHO with COVID-19 [DOI] 10.1371/journal.pone.0252389 PMC 바로가기 [Article Type] Research Article
The role of antirheumatics in patients with COVID-19Review article Published on 2021-06-012022-10-05 Journal: The Lancet Rheumatology [Category] 임상, [키워드] absence acute respiratory distress affected Anti-inflammatory anti-rheumatic drug Baricitinib Clinical characteristics clinical trial clinical utility comparability COVID-19 COVID-19 pandemic COVID-19 related mortality death defined Dexamethasone disease drug Efficacy and safety Evidence glucocorticoid heterogeneity hospitalised patient hyperinflammation Hypothesis identify immune immune response immunosuppressive drugs inclusion criteria inhibitor initial interleukin-6 less management optimal dose organ support oxygen support Patient patients with COVID-19 patients with moderate reduce review rheumatological risk severe COVID-19 shown Stage subsequent suggested syndrome therapy Time to recovery Treatment Trial [DOI] 10.1016/S2665-9913(21)00062-X [Article Type] Review article
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trialClinical Trial Published on 2021-05-012022-10-05 Journal: Stem cells translational medicine [Category] SARS, 임상, 진단, [키워드] 1:1 24 hour acute respiratory distress AEs analyzed anti-inflammatory effect ARDS Cell cell transplantation cellular cellular therapy clinical trials Control control group COVID-19 cytokine death determine distress double-blind Effect Efficacy Endpoint event group groups high mortality immunomodulatory improved patient survival intention to treat intravenous infusion mesenchymal stem cell Mesenchymal stem cells patient survival Randomized Randomized controlled trial randomized, controlled trial respiratory tract SAEs Safe secondary Serious Adverse Event severity significantly Standard of care stem cell Stratification subject survival syndrome Time to recovery transplantation Treatment treatment group UC-MSC umbilical Umbilical cord was performed was used with COVID-19 [DOI] 10.1002/sctm.20-0472 PMC 바로가기 [Article Type] Clinical Trial
Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points주요 업데이트: COVID-19 성인을 위한 Remdesivir : American College of Physicians Practice Points를 위한 살아있는 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-05-012022-09-11 Journal: Annals of internal medicine [Category] Fulltext, SARS, 치료제, [키워드] assessment baseline benefit Bia clinically college controlled trials coronavirus disease Coronavirus disease 2019 Course COVID-19 decrease Department development disease severity Effect Evidence Final GRADE greater hospital Hospitalized IMPROVE include increase in Major mechanical ventilation Meta-analysis moderate Mortality New outcomes Patient patients with COVID-19 physician Point Practice proportion Randomized controlled trial RCT RCTs receiving reduce reduce mortality reduction in reduction in mortality Remdesivir review risk risk ratio Serious Adverse Event Serious Adverse Events severity Time to recovery Treatment Ventilation veteran were used with COVID-19 [DOI] 10.7326/M20-8148 PMC 바로가기 [Article Type] Meta-Analysis
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial영국에서 불리한 임상 경과의 위험이 높은 사람들에서 COVID-19가 의심되는 지역사회 치료를 위한 아지스로마이신(원칙): 무작위, 통제, 공개, 적응 플랫폼 시험Randomized Controlled Trial Published on 2021-03-202022-08-13 Journal: Lancet (London, England) [Category] Fulltext, SARS, 임상, 치료법, [키워드] adaptive Adaptive platform trial Admission analysed anti-inflammatory properties antibiotic Antibiotics antimicrobial resistance Antiviral assigned Azithromycin azothromycin Bayesian Bayesian logistic regression model Bayesian piecewise exponential Bayesian primary analysis BCI benefit both groups Clinical course clinically Community Comorbidity complications COVID-19 credibility interval death Department Effectiveness Eligible participants Endpoint enrolled Evidence evidence of finding Follow-up funding groups hazard ratio hospital Hospital admission hospitalisation hospitalised implication in both groups increased risk Innovation Intervention ISRCTN leads less logistic regression model median time multi-arm Older Open-label outcome pandemic participant platform primary analysis primary care principle Probability provided randomisation randomised Randomised trial Randomly recruited reducing Registered reported risk Safety safety analysis study group Time to recovery treat Treatment Trial use of antibiotics usual care usual care alone usual care group [DOI] 10.1016/S0140-6736(21)00461-X PMC 바로가기 [Article Type] Randomized Controlled Trial
Homeopathy for Covid-19 in Primary Care: A structured summary of a study protocol for a randomized controlled trial일차 진료에서 Covid-19에 대한 동종 요법: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-02-012022-08-31 Journal: Trials [Category] MERS, 임상, 치료제, [키워드] 1:1 6 hour 6 hours acute respiratory syndrome Adverse adverse events alcohol alternative hypothesis appearance blinded Blinding block randomization bottle Brazil changed changes chest pain clinical trial cough COVID-19 defined dissemination dose double-blind Effectiveness elapsed element emergency services Fever followed by headache Home isolation homeopathic medicine homeopathic medicines Homeopathy hospitalizations identity Influenza Influenza-like symptoms Informed consent investigators measure medication Medicine Medicines Mild mild case mild cases muscle aches network null hypothesis number objective Older outcome Pain participant performed Placebo placebo-controlled positive RT-PCR primary care primary endpoint Primary Health Care protocol randomisation randomised Randomized Randomized controlled trial Randomized Controlled Trial protocol recorded Recovery time recruitment Registered required respiratory Sample size SARS-CoV-2 secondary Severe acute respiratory syndrome shakes sore throat statistician status study medication Study protocol submitted supplementary material Symptom Telemedicine Time to recovery tiredness treatment group Trial two group two groups Unified Health System university website without symptoms [DOI] 10.1186/s13063-021-05071-5 PMC 바로가기 [Article Type] Letter
Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice PointsCOVID-19가 있는 성인을 위한 렘데시비르: 미국 의사 학회(American College of Physicians) 실습 포인트에 대한 살아있는 체계적인 검토Article Published on 2021-02-012022-09-11 Journal: Annals of internal medicine [Category] Fulltext, SARS, 임상, 치료제, [키워드] age ARD assessment assessments benefit certainty Clinical improvement college coronavirus disease Coronavirus disease 2019 Course COVID-19 Department development disease severity drug Effectiveness evaluate Evidence excluded extracorporeal membrane oxygenation food health administration hospital Hospitalized hospitalized patient hospitalized patients IMPROVE kidney kidney or liver disease Liver disease mechanical ventilation moderate New no effect office Open-label open-label trials physician Placebo Point Practice pregnant women preliminary report Program randomized trial receiving reduce reduce mortality reduction in mortality Remdesivir research and development review risk risk difference searched Serious Adverse Event Serious Adverse Events service severe COVID-19 Sex symptom duration synthesis Time to recovery Treatment trials U.S. Food and Drug Administration veteran website with COVID-19 [DOI] 10.7326/M20-5752 PMC 바로가기 [Article Type] Article